| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ceftazidime hydrate (Fortaz; Fortum; GR20263; LY-139381; GR-20263), the hydrated form of Ceftazidime, is a 3rd generation, broad-spectrum β-lactam antibiotic/cephalosporin antibiotic useful for the treatment of a number of bacterial infections.
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
Antibacterial and anti-biofilm properties against P. aeruginosa strains are demonstrated by ceftazidime (0-8 µg/mL, approx., 24 h) pentahydrate[2].
Ceftazidime pentahydrate (0–40 µg/mL, approximately; 18–20 h) exhibits inhibitory effects on isolates of S. maltophilia[3]. |
| ln Vivo |
In a murine thigh infection model, ceftazidime (2 h infusion of injection, 2 000 mg, every 8 h for 24 h) pentahydrate moderately reduces bacterial density[4].
|
| Cell Assay |
Cell Line: P. aeruginosa strains (PAO1, PA1, PA2)
Concentration: 0-8 µg/mL approximately Incubation Time: 24 h Result: demonstrated MIC values of 2-4 µg/mL for antibacterial and anti-biofilm activities. |
| Animal Protocol |
Animal Model: Murine thigh infection model[4]
Dosage: 2000 mg Administration: 2 h infusion of injection, every 8 h for 24 h. Result: decreased bacterial density when compared to the isogenic strain of NDM (New Delhi metallo-β-lactamase). |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Avibactam has not been studied in nursing mothers. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Ceftazidime-avibactam is acceptable in nursing mothers. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. ◉ Summary of Use during Lactation Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Ceftazidime and is acceptable in nursing mothers. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
| References |
|
| Additional Infomation |
Ceftazidime pentahydrate is a hydrate that is the pentahydrate of ceftazidime, a cephalosporin having 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino and 3-pyridinium-1-ylmethyl side-groups. It contains a ceftazidime.
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. |
| Exact Mass |
546.099
|
|---|---|
| Elemental Analysis |
C, 41.51; H, 5.07; N, 13.20; O, 30.16; S, 10.07
|
| CAS # |
78439-06-2
|
| Related CAS # |
Ceftazidime;72558-82-8
|
| PubChem CID |
6536864
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>150ºC(dec.)
|
| LogP |
-2.84
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
42
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
|
| InChi Key |
NMVPEQXCMGEDNH-CYWOSJMDSA-N
|
| InChi Code |
InChI=1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)5*1H2/b26-13-/t14-,18-/m0...../s1
|
| Chemical Name |
(6S,7S)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
pentahydrate
|
| Synonyms |
Ceftazidime; Anhydrous, Ceftazidime;Ceftazidime; Ceftazidime Anhydrous; Ceftazidime Pentahydrate; Fortaz; Fortum; GR 20263; GR-20263; GR20263; LY 139381; LY-139381; LY139381; Pentahydrate, Ceftazidime; Tazidime;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 2~100 mg/mL (3.65~157.07 mM)
Water : ~25 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.93 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
